EA201270206A1 - Копреципитат, включающий ингибитор фосфодиэстеразы-5 (pde-5-ингибитор) и фармацевтически совместимый носитель, его получение и применение - Google Patents
Копреципитат, включающий ингибитор фосфодиэстеразы-5 (pde-5-ингибитор) и фармацевтически совместимый носитель, его получение и применениеInfo
- Publication number
- EA201270206A1 EA201270206A1 EA201270206A EA201270206A EA201270206A1 EA 201270206 A1 EA201270206 A1 EA 201270206A1 EA 201270206 A EA201270206 A EA 201270206A EA 201270206 A EA201270206 A EA 201270206A EA 201270206 A1 EA201270206 A1 EA 201270206A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitor
- pde
- phosphodesterase
- coprecipitation
- receiving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Данное изобретение относится к копреципитату, включающему ингибитор фосфодиэстеразы-5 (PDE-5-ингибитор) и фармацевтически совместимый сополимер-носитель, состоящий из 2 или более различных производных акриловой кислоты, способ получения данного копреципитата, а также лекарственное средство, включающее копреципитат по изобретению, способ получения данного лекарственного средства и применение данного лекарственного средства для лечения заболеваний, при которых необходимо терапевтическое ингибирование фосфодиэстеразы-5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009035211A DE102009035211A1 (de) | 2009-07-29 | 2009-07-29 | Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung |
PCT/EP2010/004181 WO2011012217A2 (de) | 2009-07-29 | 2010-07-08 | Copräzipitate umfassend einen phosphodiesterase-5-inhibitor (pde-5-inhibitor) und einen pharmazeutisch verträglichen trägerstoff, ihre herstellung und verwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201270206A1 true EA201270206A1 (ru) | 2012-07-30 |
EA022037B1 EA022037B1 (ru) | 2015-10-30 |
Family
ID=42646808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201270206A EA022037B1 (ru) | 2009-07-29 | 2010-07-08 | Копреципитат, включающий ингибитор фосфодиэстеразы-5 (pde-5-ингибитор) и фармацевтически совместимый носитель, его получение и применение |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120189694A1 (ru) |
EP (1) | EP2459174A2 (ru) |
DE (1) | DE102009035211A1 (ru) |
EA (1) | EA022037B1 (ru) |
WO (1) | WO2011012217A2 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
WO2014202797A1 (en) * | 2013-07-05 | 2014-12-24 | Synthon B.V. | Pharmaceutical composition comprising a solid dispersion of tadalafil |
WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
SI3466951T1 (sl) * | 2014-07-23 | 2022-05-31 | Krka, D.D., Novo Mesto | Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0297866A3 (en) * | 1987-07-01 | 1989-12-13 | The Boots Company PLC | Therapeutic agents |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
IL147641A0 (en) | 1999-08-03 | 2002-08-14 | Lilly Icos Llc | Beta-carboline pharmaceutical compositions |
UA71629C2 (en) | 1999-08-03 | 2004-12-15 | Lilli Icos Llc | Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction |
US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US20080226723A1 (en) * | 2002-07-05 | 2008-09-18 | Celonova Biosciences, Inc. | Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same |
BRPI0621852A2 (pt) * | 2006-07-07 | 2011-12-20 | Teva Pharma | compostos sólidos consistindo de tadalafil e pelo menos um veìculo |
US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
US9233078B2 (en) * | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
-
2009
- 2009-07-29 DE DE102009035211A patent/DE102009035211A1/de not_active Withdrawn
-
2010
- 2010-07-08 US US13/387,276 patent/US20120189694A1/en not_active Abandoned
- 2010-07-08 WO PCT/EP2010/004181 patent/WO2011012217A2/de active Application Filing
- 2010-07-08 EP EP10730104A patent/EP2459174A2/de not_active Ceased
- 2010-07-08 EA EA201270206A patent/EA022037B1/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2011012217A2 (de) | 2011-02-03 |
DE102009035211A1 (de) | 2011-02-17 |
DE102009035211A8 (de) | 2011-05-19 |
US20120189694A1 (en) | 2012-07-26 |
EA022037B1 (ru) | 2015-10-30 |
WO2011012217A3 (de) | 2012-04-26 |
EP2459174A2 (de) | 2012-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202303227B (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
MX2011008448A (es) | Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia. | |
EA201001577A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
EA201270041A1 (ru) | Лечение рассеянного склероза лаквинимодом | |
CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
MX341212B (es) | Inhibidor de bromodominio de benzodiazepina. | |
UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
EA201300558A1 (ru) | Соединения и способы для купирования боли | |
WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
UY32487A (es) | Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona | |
EA200900343A1 (ru) | Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик | |
WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
EA201101435A1 (ru) | Имидазотиадиазолы для применения в качестве ингибиторов киназ | |
GB0620385D0 (en) | Novel compounds | |
EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
MY156302A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
IN2012DN05186A (ru) | ||
EA201370230A1 (ru) | Новые ингибиторы rock | |
EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
EA200701615A1 (ru) | Новые лекарственные средства для лечения заболеваний дыхательных путей | |
EA201270206A1 (ru) | Копреципитат, включающий ингибитор фосфодиэстеразы-5 (pde-5-ингибитор) и фармацевтически совместимый носитель, его получение и применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ RU |